Document is current
Any future updates will be listed below
-
Authors
Pensato, Viviana
Peverelli, Silvia
Tiloca, Cinzia
Magri, Stefania
Brusati, Alberto
Pingue, Monica
Morelli, Claudia
Dalla Bella, Eleonora
Manini, Arianna
Tannorella, Pierpaola
Doretti, Alberto
Mandrioli, Jessica
Terenghi, Fabrizia
Prelle, Alessandro
Riva, Nilo
Verde, Federico
Eleopra, Roberto
Taroni, Franco
Lauria Pinter, Giuseppe
Silani, Vincenzo
Ticozzi, Nicola
Gellera, Cinzia
Ratti, Antonia https://orcid.org/0000-0002-4264-6614
-
Funding
Funding for this research was provided by:
Ministero della Salute (GR-2016-02364373)
- License Information
-
More Information
Article History
Received: 13 February 2025
Revised: 14 April 2025
Accepted: 6 May 2025
First Online: 19 June 2025
Declarations
:
: V.S. received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., Novartis Pharma AG, Amylyx Pharmaceuticals, Biogen, and Zambon Biotech SA. He is in the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology, and Exploration of Neuroprotective Therapy.
: Approval for this study was obtained from the ethical committees of the participating Institutions (REB approval 2018_04_17) and studies have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Informed consent was obtained from all individual participants included in the study.
